Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic

•First real-world complete look at ofatumumab initiation during COVID-19 pandemic.•Baseline enrollment covered a wide age range and included patients aged ≥55 years.•At 9 months post-approval, the use of ofatumumab as a first-line therapy increased.•Treatment-experienced patients often switched from ocrelizumab to ofatumumab.